Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 284 results
A test tube with a colorful chemical solution on a lab bench

May 26, 2026

Exclusive: Ex-Palantir AI execs raise $12 million seed round for Perceptic, a startup automating drug discovery

Perceptic, a startup founded by former Palantir executives, has emerged from stealth mode with a $12 million seed funding round aimed at revolutionizing drug discovery through an end-to-end AI platform. The company, which has already garnered interest from major pharmaceutical firms, is designed to streamline the drug development process from discovery to clinical trial design.The funding round was led by Accel, with participation from Air Street Capital and Elder Gull. Although the company has
A minimalist representation of a bispecific antibody in flat design.

May 26, 2026

Biomunex Pharmaceuticals Embraces AI with Two New Strategic Collaborations

Biomunex Pharmaceuticals is enhancing its research capabilities through two new partnerships with AI-focused firms, Gordion Bioscience and Tangramed Biotech.The collaborations aim to integrate artificial intelligence into Biomunex's scientific workflows, particularly in the realm of immunotherapy development. By leveraging AI technologies, the company seeks to expedite the discovery and refinement of innovative treatments for cancer, focusing on bispecific and multi-specific antibodies.These str
A minimalist representation of a drug compound in a dark palette.

May 26, 2026

AI drug discovery deal targets faster biotech hit validation

A new partnership between Concept Life Sciences and OpenBench aims to revolutionize the early stages of drug discovery for biotech firms by leveraging artificial intelligence to streamline hit validation processes.The collaboration combines OpenBench’s AI-driven structure-based platform with Concept Life Sciences’ expertise in medicinal chemistry and validation services. This integrated approach is designed to expedite the transition from target identification to validated hit series in just six
A drug compound in a glass vial on a lab bench with shelves of reagents in the background.

May 25, 2026

Machine learning brings speed to pharma’s slowest pipeline

Machine learning is revolutionizing the drug discovery process by enhancing efficiency in target identification and compound selection, yet it faces challenges in validation and integration with existing workflows.Recent research published in *Pharmaceuticals* emphasizes the transformative role of machine learning (ML) in drug discovery, particularly in the early stages where researchers select targets and evaluate molecular candidates. The study advocates for ML as a complementary tool to exper
A vial of medication on a lab bench

May 25, 2026

Can Nvidia’s Backing Reframe Generate Biomedicines (GENB) as a Scaled AI Drug Developer?

Nvidia's recent investment in Generate Biomedicines highlights a significant shift in the biotech landscape, particularly in AI-driven drug development. The $10.40 million funding aims to bolster Generate's clinical pipeline, which includes advanced therapies for severe asthma and oncology, currently under FDA Fast Track status.This investment not only validates Generate Biomedicines' approach but also emphasizes the growing traction of AI in real-world drug discovery. However, the company faces
A small-molecule drug compound on a lab bench in a biopharmaceutical lab

May 24, 2026

Redwood AI’s Data Boom and Defense Push Contrast With Silent Pharma Pact

Redwood AI is making strides in both the defense and pharmaceutical sectors, yet its stock remains volatile due to a lack of financial clarity.The Canadian AI company has recently announced a partnership with Resilience Biosciences, a biopharmaceutical firm focused on developing non-opioid therapies. This collaboration will utilize Redwood’s advanced software for designing small-molecule drug candidates. However, the absence of financial specifics in the announcement has left investors uncertain
A vial of enzyme sample on a lab bench with shelves of reagents in the background.

May 21, 2026

Imperagen’s £5M Bid Powers AI Enzyme Design Leap

Imperagen has secured £5 million in funding to enhance its AI-driven enzyme design platform, aiming to revolutionize the biocatalyst development landscape.The latest funding round brings Imperagen's total to £8.5 million since its inception in 2021, allowing the company to expand its research and development efforts in AI enzyme design. This financial boost will support hiring in key areas such as computational chemistry and automation, with plans to double its workforce within the next year. Th
A minimalist representation of an enzyme and chemical bond in dark colors with lime accents.

May 21, 2026

Manchester AI biotech spin-out lands £5m to “rewrite chemical reactions”

Manchester-based biotech spin-out Imperagen has successfully raised £5 million in seed funding to enhance its AI-driven enzyme engineering platform, a venture stemming from research conducted at The University of Manchester.This funding round, led by PXN Ventures with participation from existing investors IQ Capital and Northern Gritstone, brings Imperagen's total funding to £8.5 million. Established in 2021 by researchers Dr. Andrew Almond, Dr. Andrew Currin, and Dr. Tim Eyes, the company aims
A test tube with a colorful chemical solution in a dimly lit lab

May 21, 2026

Concept Life Science and OpenBench team up on AI-driven hit discovery platform for biotechs

Concept Life Sciences and OpenBench have formed a strategic alliance aimed at enhancing hit identification for biotech firms through an innovative fee-for-success model.This partnership merges OpenBench's AI-driven, structure-based discovery platform with Concept Life Sciences' expertise in medicinal chemistry and in-vitro screening. The collaboration promises to expedite the journey from target identification to validated hit series, potentially within a six-month timeframe. OpenBench's model a
A minimalist illustration of a molecule and a computer chip, symbolizing AI in drug discovery.

May 21, 2026

QIAGEN Partners with NVIDIA to Expand AI Drug Discovery

QIAGEN has announced a strategic partnership with NVIDIA to enhance AI-driven drug discovery and biomedical research.This collaboration aims to integrate NVIDIA's advanced computing capabilities and the BioNeMo platform into QIAGEN Digital Insights (QDI). By combining QIAGEN’s extensive biological and bioinformatics resources with NVIDIA's AI technologies, the partnership seeks to improve data analysis, biomarker discovery, and target identification throughout the drug development process.The in
A test tube with a colorful liquid sample in a laboratory setting

May 21, 2026

QIAGEN and NVIDIA partner on AI drug discovery

QIAGEN has announced a strategic partnership with NVIDIA to enhance AI-driven drug discovery through advanced computing and the BioNeMo platform, unveiled at the 2026 BIO-IT World Conference & Expo.This collaboration aims to merge QIAGEN’s extensive biomedical knowledge with cutting-edge artificial intelligence, thereby streamlining processes in drug discovery, target identification, and biomarker research. By leveraging this integration, pharmaceutical and biotechnology researchers will be bett
An enzyme sample on a lab surface in a dimly lit laboratory

May 21, 2026

Imperagen Raises €5.8M Seed for AI and Quantum Enzyme Engineering

Imperagen, a Manchester-based biotech firm, has secured €5.8 million in seed funding to enhance its innovative enzyme engineering platform, which utilizes AI and quantum simulation technologies.Recently, Imperagen announced the closing of a £5 million (~€5.8 million) seed funding round led by PXN Ventures, with participation from existing investors IQ Capital and Northern Gritstone. This funding brings the company's total investment to £8.5 million since its inception in 2021. The new capital wi